
    
      This is a phase 4, multicenter, randomized, double-blind, parallel-group, comparative study
      using placebo (Treatment Period I) and a phase 4, multicenter, open-label, long-term study
      (Treatment Period II) to evaluate the efficacy and safety of SYR-472 when administered at a
      dose of 100 mg as an add-on to insulin therapy in patients with type 2 diabetes mellitus and
      inadequate glycemic control despite treatment with insulin preparations in addition to diet
      and/or exercise therapy.
    
  